The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants

被引:71
作者
Ceccarelli, Jenny [1 ]
Delfino, Laura [1 ]
Zappia, Emanuela [1 ]
Castellani, Patrizia [1 ]
Borghi, Martina [2 ]
Ferrini, Silvano [2 ]
Tosetti, Francesca [1 ]
Rubartelli, Anna [1 ]
机构
[1] Natl Inst Canc Res, Cell Biol Unit, I-16132 Genoa, Italy
[2] Natl Inst Canc Res, Immunotherapy Unit, I-16132 Genoa, Italy
关键词
thioredoxin; non protein thiols; reduction/oxidation; arsenic trioxide; MIF;
D O I
10.1002/ijc.23709
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Here we report that human nonsmall cell lung carcinomas overexpress macrophage migration inhibitory factor (MIF) and thioredoxin (Trx), 2 oxidoreductases with cytokine function. and contain more abundant nonprotein thiols (glutathione and cysteine) than nonneoplastic lung tissues. Cell clones derived from the same lung carcinoma cell lines but expressing different levels of Trx and/or MIF displayed growth rates in vitro and in vivo correlating with Trx but not with MIF. Interestingly, the different clones generate extracellularly reduced nonprotein thiols, in amounts related to the Trx content and inhibited by inhibitors of Trx function. Each clone also showed distinct responses to the prooxidant compound arsenic trioxide. Cells with a strongly antioxidant and aggressive phenotype were more susceptible to the cytotoxic effect of the drug than cells expressing little Trx. The latter counteracted the oxidative stress by increasing Trx expression and thiol release. Together these results indicate that different human lung cancer cell lines have distinct redox properties defined by the levels of Trx and nonprotein thiols, the higher antioxidant phenotype correlating with the higher aggressiveness. Moreover, the redox phenotype dictates their response to prooxidant drugs and must be taken into account when therapeutic interventions with redox active substances are considered. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:1770 / 1778
页数:9
相关论文
共 53 条
[1]   Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation [J].
Angelini, G ;
Gardella, S ;
Ardy, M ;
Ciriolo, MR ;
Filomeni, G ;
Di Trapani, G ;
Clarke, F ;
Sitia, R ;
Rubartelli, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1491-1496
[2]   The thioredoxin system in cancer [J].
Arner, Elias S. J. ;
Holmgren, Arne .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) :420-426
[3]   1-CHLORO-2,4-DINITROBENZENE IS AN IRREVERSIBLE INHIBITOR OF HUMAN THIOREDOXIN REDUCTASE - LOSS OF THIOREDOXIN DISULFIDE REDUCTASE-ACTIVITY IS ACCOMPANIED BY A LARGE INCREASE IN NADPH OXIDASE ACTIVITY [J].
ARNER, ESJ ;
BJORNSTEDT, M ;
HOLMGREN, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (08) :3479-3482
[4]   Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme [J].
Bacher, M ;
Schrader, J ;
Thompson, N ;
Kuschela, K ;
Gemsa, D ;
Waeber, G ;
Schlegel, J .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (01) :11-17
[5]   The antitumor agent imexon activates antioxidant gene expression: Evidence for an oxidative stress response [J].
Baker, Amanda F. ;
Landowski, Terry ;
Dorr, Robert ;
Tate, Wendy R. ;
Gard, Jaime M. C. ;
Tavenner, Breonna E. ;
Dragovich, Tomislov ;
Coon, Amy ;
Powis, Garth .
CLINICAL CANCER RESEARCH, 2007, 13 (11) :3388-3394
[6]   Smoldering and polarized inflammation in the initiation and promotion of malignant disease [J].
Balkwill, F ;
Charles, KA ;
Mantovani, A .
CANCER CELL, 2005, 7 (03) :211-217
[7]   Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1 [J].
Baugh, John A. ;
Gantier, Michael ;
Li, Lili ;
Byrne, Aileen ;
Buckley, Avril ;
Donnelly, Seamas C. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 347 (04) :895-903
[8]   Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators [J].
Ben-Baruch, A .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (01) :38-52
[9]  
BERGER SJ, 1994, CANCER RES, V54, P4077
[10]  
Biaglow JE, 2005, CANCER BIOL THER, V4, P6